At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 192 enrolled
Drug / intervention
Bempegaldesleukin +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Bempegaldesleukin and Nivolumab for Urinary Bladder Neoplasm and Neoplasm Metastasis. Completed, enrolled 192 participants across 70 sites in 18 countries.
Detailed Summary
The main purpose of this study is to evaluate the anti-tumor activity of bempegaldesleukin (NKTR-214) in combination with nivolumab by assessing the objective response rate (ORR) in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder Neoplasm, Neoplasm Metastasis
CountriesArgentina, Australia, Belgium, Canada, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Portugal, Russia, Spain, Turkey (Türkiye), United Kingdom, United States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartApr 2019
Primary CompletionFeb 2022
Study CompletionJun 2022
TodayJul 2026
First PostedDec 24, 2018
Enrollment StartApr 29, 2019
Primary CompletionFeb 9, 2022
Study CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 7.5 years ago
Interventions
Bempegaldesleukinbiological
Specified dose on specified days
Nivolumabbiological
Specified dose on specified days